Daisuke Matsuo

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark.

Part of Asahi Kasei Corp., Asahi Kasei Pharma Corp. is a pharmaceutical and diagnostic company based in Tokyo, Japan. Asahi Kasei Pharma operates in the healthcare business unit of the Asahi Kasei Group, with a mission to sincerely care for each individual life and solve their unmet medical needs with a wealth of ideas and solid science. Asahi Kasei Corp. is a US $20 billion Japanese technology company that provides innovative, science-based solutions to a diverse range of markets including healthcare, chemicals and fibers, housing and construction materials, and electronics. Founded in 2003, the company has developed innovative drugs in the fields of orthopedics, acute care, neurology (including pain), and immunology.